Trends in rural-urban disparities in U.S. cervical cancer mortality before and after the HPV vaccine introduction: A CDC analysis, 1999-2023.

J Jasvindar Kumar (PGY 3 IM, Bassett Medical Center, Cooperstown, NY) H Hameer Ali (Chandka Medical College, Larkana, Pakistan) A Ayesha Mudassar (King Edward Medical University, Lahore, Pakistan) U Umm-e- Aimen (Faisalabad Medical University, Faisalabad, Pakistan) A Anushah Faheem Ilyas (Karachi Medical and Dental College, Karachi, Pakistan) Z Zain Ali N Noor Fatima M Muhammad Idrees S Steve Oguguo Nwokeocha (PGY 2 IM, Bassett Medical Center, Cooperstown, NY) J Jeffrey P. Allerton (Bassett Medical Center, Cooperstown, NY)

Abstract

5535 Background: Cervical cancer mortality has declined in the United States following the introduction of HPV vaccination. However, disparities by urbanization, geography, and race may persist. Rural women remain up to 40% more likely to die from cervical cancer. Understanding rural–urban trends is essential to guiding equitable prevention strategies. Methods: CDC WONDER mortality data for females ≥15years with cervical cancer (ICD-10 C53) were analyzed. Age-adjusted mortality rates (AAMR) per 100,000 population were analyzed. Urbanization data were available till 2020 and were used for urban–rural stratification (NCHS classification). Temporal trends were assessed using joint point regression to determine average annual percent change (AAPC). Results: Between 1999 and 2023, 102,205 cervical cancer deaths were identified. The overall AAMR declined from 1.52 to 1.28 during the pre-vaccine era (1999–2005; AAPC = –2.95%, 95% CI –4.0 to –1.8) and further to 1.09 during the post-vaccine era (2006–2023; AAPC = –0.86%, 95% CI –1.0 to –0.7). Rural-urban mortality (AAMR) ratio increased in post-vaccine era from 1.13 vs 1.15 with 1.47% increase in disparity. By urbanization, declines were greatest in central metropolitan areas (AAMR 1.72 to 1.48 pre-vaccine; 1.14 post-vaccine; AAPC = –1.40%, 95% CI –1.6 to –1.2), while small metro (1.36 to 1.29 pre-vaccine; 1.11 post-vaccine; AAPC = –0.93%, 95% CI –1.2 to –0.6) and micropolitan areas (1.70 to 1.44 pre-vaccine; 1.32 post-vaccine; AAPC = –0.34%, 95% CI –1.3 to 0.6) showed slower improvement which widened mortality gap. Subgroup analyses showed the steepest mortality declines among women aged ≥75 years (AAPC = –3.66%), among Black women (AAPC = –2.81%), and in the Northeast region (AAPC = –2.16%). Conclusions: U.S. cervical cancer mortality declined after the HPV vaccine introduction; however, rural–urban, racial, and regional disparities persisted. Declines were slower in small metropolitan and nonmetropolitan areas and highest among Black individuals, underscoring the need for targeted vaccination, screening efforts and access-to-care.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 5535-5535
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (10)

J

Jasvindar Kumar

PGY 3 IM, Bassett Medical Center, Cooperstown, NY

H

Hameer Ali

Chandka Medical College, Larkana, Pakistan

A

Ayesha Mudassar

King Edward Medical University, Lahore, Pakistan

U

Umm-e- Aimen

Faisalabad Medical University, Faisalabad, Pakistan

A

Anushah Faheem Ilyas

Karachi Medical and Dental College, Karachi, Pakistan

Z

Zain Ali

N

Noor Fatima

M

Muhammad Idrees

S

Steve Oguguo Nwokeocha

PGY 2 IM, Bassett Medical Center, Cooperstown, NY

J

Jeffrey P. Allerton

Bassett Medical Center, Cooperstown, NY